Pharma and healthcare: sector news on Friday 6 November 2026
Average tone +0.4 (neutral) across 5 companies with relevant coverage, from 56 stories.
How to read a score. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Company by company
| Company | Tone | Stories | What the coverage was about |
|---|---|---|---|
| AstraZeneca | +4.0 | 37 | Coverage was dominated by reports of a roughly $10bn offer for Rhythm Pharmaceuticals, which is viewed mildly positively as an expansion in rare disease and obesity. |
| GSK | +4.5 | 8 | Coverage was mainly about a cancer drug approval, liver pipeline updates and a $100M HIV care pledge from ViiV, which lean positive. |
| Haleon | −2.8 | 5 | Coverage was mostly light commentary, with a minor brand award for Stresstabs on the positive side. |
| Smith & Nephew | −6.8 | 5 | Coverage centred on Smith & Nephew reducing its 2026 profit forecast although third-quarter revenue grew 3.4%, with the shares dropping and talks with J&J finishing. |
| Convatec | +3.0 | 1 | Coverage was a single sector commentary piece asking whether medtech sentiment is helping Convatec. |
Strongest stories in the sector
- −9.7 Shares dropped on guidance cut; talks with J&J ended, leaving orthopaedics options open.
- −8.7 Lowered full-year profit guidance outweighs modest third-quarter sales growth.
- +8.3 Regulatory approval for cancer drug supports valuation view
- +7.5 Indian subsidiary posts strong quarter and shares jump sharply.
- −7.0 Lowered growth outlook questions investment case.
- +6.7 Indian unit's quarterly profit increased.
- +6.7 Indian unit profit up with growth across main therapy areas.
- +6.7 Subsidiary's quarterly sales grew strongly.
- +6.3 Indian unit's quarterly sales well ahead of prior year.
- +6.3 Indian subsidiary reports strong quarterly sales growth.
- +5.8 Broker keeps positive recommendation on the shares.
- +5.8 Company seen as bellwether for UK healthcare shares.
Pharma and healthcare: every day · FTSE 100 overview for the day
Follow by email
A short, free morning email on how the news treated the Pharma and healthcare sector: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.